# Pulmonary Resectable Osteosarcoma Treated by Metastasectomy and Pre-operative Immunotherapy and Stereotactic Body Radiotherapy (PROMIS): a Prospective Clinical Trial

> **NCT06114225** · PHASE2 · RECRUITING · sponsor: **Ruijin Hospital** · enrollment: 43 (estimated)

## Conditions studied

- Osteosarcoma

## Interventions

- **COMBINATION_PRODUCT:** metastasectomy and pre-operative immunotherapy (gemcitabine and penpulimab ) and stereotactic body radiotherapy

## Key facts

- **NCT ID:** NCT06114225
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-06-01
- **Primary completion:** 2026-09-15
- **Final completion:** 2026-12-30
- **Target enrollment:** 43 (ESTIMATED)
- **Last updated:** 2023-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06114225

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06114225, "Pulmonary Resectable Osteosarcoma Treated by Metastasectomy and Pre-operative Immunotherapy and Stereotactic Body Radiotherapy (PROMIS): a Prospective Clinical Trial". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06114225. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*